Nephroprotective potential of glucagon-like peptide-1 receptor agonists

por Minara S. Shamkhalova, Igor A. Sklyanik, Marina V. Shestakova
Publicado 2020

Advances in Subcutaneous Delivery Systems of Biomacromolecular Agents for Diabetes Treatment

por Li C, Wan L, Luo J, Jiang M, Wang K
Publicado 2021

Mechanisms of neuroprotective action of incretin mimetics

por Timur Dmitrievich Vlasov, Anna Vladimirovna Simanenkova, Svetlana Vladimirovna Dora, Evgeniy Vladimirovich Shlyakhto
Publicado 2016

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-compar...

por Orme ME, Nguyen H, Lu JY, Thomas SA
Publicado 2017

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date

por Howell R, Wright AM, Clements JN
Publicado 2019

Diabetes and Colorectal Cancer Risk: A New Look at Molecular Mechanisms and Potential Role of Novel Antidiabetic Agents

por Jelena Vekic, Aleksandra Zeljkovic, Aleksandra Stefanovic, Rosaria Vincenza Giglio, Marcello Ciaccio, Manfredi Rizzo
Publicado 2021

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice

por Lee J, Cho YK, Kim HS, Jung CH, Park JY, Lee WJ
Publicado 2019

Risk of Thyroid Cancer Associated with Use of Liraglutide and Other Antidiabetic Drugs in a US Commercially Insured Population

por Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Zhou L, Ng E, Ross D, Major-Pedersen A, Bosch-Traberg H, Gydesen H, Dore DD
Publicado 2021

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data

por Kugler AJ, Thiman ML
Publicado 2018

Is there an association between liraglutide use and female breast cancer in a real-world setting?

por Funch D, Mortimer K, Li L, Norman H, Major-Pedersen A, Olsen AH, Kaltoft MS, Dore DD
Publicado 2018

Adjunctive therapy for glucose control in patients with type 1 diabetes

por Harris K, Boland C, Meade L, Battise D
Publicado 2018

To Assess Liraglutide’s Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System

por Yin J, Han M, Li L, Li Y, Liu Z, Yang J, Liu Y
Publicado 2021

Safety of Semaglutide

por Mark M. Smits, Daniël H. Van Raalte
Publicado 2021

Corrigendum: Safety of Semaglutide

por Mark M. Smits, Daniël H. Van Raalte
Publicado 2021

Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo

por Yanbin Dong, Jamie Carty, Nitsan Goldstein, Zhenyan He, Eunsang Hwang, Dominic Chau, Briana Wallace, Anita Kabahizi, Linh Lieu, Yunqian Peng, Yong Gao, Ling Hu, J. Nicholas Betley, Kevin W. Williams
Publicado 2021